Indeed, acquired CYP19A1 (encoding aromatase) amplification in BC cells has been found in 21.5% of relapsed AI-treated patients, and this alteration causes autonomous estrogen biosynthesis that activates ERα [15]. Here, ESR1 is linked to breast cancer.